36 results on '"Schlamm, Haran T"'
Search Results
2. Fosmanogepix Therapy of Disseminated Fusarium Infection
3. Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group
4. Combination Therapy for Invasive Aspergillosis: Controversies and Conclusions
5. Ocular Manifestations of Candidemia
6. Early Proinflammatory Cytokines and C-Reactive Protein Trends as Predictors of Outcome in Invasive Aspergillosis
7. Review of the Basic and Clinical Pharmacology of Sulfobutylether-β-Cydodextrin (SBECD)
8. Combination Antifungal Therapy for Invasive Aspergillosis: A Randomized Trial
9. An open-label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America
10. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis
11. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign
12. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome
13. 147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial
14. 1157. Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial
15. An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity
16. Voriconazole treatment for less-common, emerging, or refractory fungal infections. (Major Article)
17. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
18. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
19. Changes in Causes of Death Over Time After Treatment for Invasive Aspergillosis
20. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis
21. Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes
22. Halo sign and improved outcome
23. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
24. Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole Versus Amphotericin B for Therapy of Invasive Aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group
25. Voriconazole or Amphotericin B as Primary Therapy Yields Distinct Early Serum Galactomannan Trends Related to Outcomes in Invasive Aspergillosis
26. An open‐label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America
27. Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis
28. Tissue Distribution of Anidulafungin in Neonatal Rats
29. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
30. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
31. Voriconazole as Therapy for Systemic Penicillium marneffei Infections in AIDS Patients
32. Nutritional and metabolic assessment of the hospitalized patient.
33. Clinical effectiveness of a pancreatic enzyme supplement.
34. Haemophilus influenzae pneumonia in young adults with AIDS, ARC, or risk of AIDS
35. Authors' response: Echinocandins -- first line in invasive candidiasis: how strong is this 'strong' evidence?
36. Ocular manifestations of candidemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.